Financial Snapshot

Revenue
$1.226B
TTM
Gross Margin
71.67%
TTM
Net Earnings
$28.45M
TTM
Current Assets
$728.3M
Q2 2023
Current Liabilities
$582.6M
Q2 2023
Current Ratio
125.01%
Q2 2023
Total Assets
$2.090B
Q2 2023
Total Liabilities
$1.197B
Q2 2023
Book Value
$892.5M
Q2 2023
Cash
$80.72M
Q2 2023
P/E
73.28
Sep 08, 2023 EST
Free Cash Flow
$73.42M
TTM

Revenues

Revenues

Revenue YoY Change

Revenues

Concept 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 2001

Expenses

Cost Of Revenues

Gross Profit

Gross Profit Margin

Gross Profit

Concept 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 2001

Selling, General & Admin Expense

Research & Development

Depreciation, Depletion & Amortization

SGA Expense to Gross Profit Ratio

R&D To Gross Profit Ratio

DDA To Gross Profit Ratio

Operating Expenses Total

Operating Profits/Loss

Operational Expenses

Concept 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 2001

Interest Expenses

Interest Expenses To Operating Income %

Other Expense/Income

Interest & Other Expense/Income

Concept 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 2001

Income/Loss

Pretax Income

Income Tax

Net Profits/Loss

Pretax Income YoY Change

Income Tax Rate

Net Profits/Loss YoY Change

Basic EPS

Net Income To Revenue Ratio

Pretax & Net Income

Concept 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 2001

Assets & Liabilities

Cash & Short-Term Investments

Cash & Equivalents

Cash To Operating Expenses Ratio

Inventory

Receivables

Total Short-Term Assets

Property, Plant And Equipment

Long-Term Investments

Total Long-Term Assets

Total Assets

Net Income To Total Assets Percentage

Accounts Payable

Short-Term Debt

Long Term Debt Due

Total Short-Term Liabilities

Long-Term Debt

Other Long-Term Liabilities

Total Long-Term Liabilities

Total Liabilities

Short-Term To Long-Term Debt Ratio

Short-Term Assets To Debt Ratio

Long-Term Debt To Net Income Ratio

Assets & Liabilities

Concept 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 2001

Ownership

Basic Shares Outstanding

Diluted Shares Outstanding

Preferred Stock

No data

Treasury Stock Shares

Stock Issuance & Repurchase

Ownership Data

Concept 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 2001

Return On Shareholders' Equity

Book Value

Free Cash Flow

Free Cash Flow YoY

Free Cash Flow Margin

Dividends

Dividends

No data

Stock Price

Market Cap: $2.0849 Billion

About NUVASIVE INC

NuVasive, Inc. engages in the development, manufacture, sale, and provision of procedural solutions for spine surgery. The company is headquartered in San Diego, California and currently employs 3,000 full-time employees. The company went IPO on 2004-05-13. The firm is focused on developing, manufacturing, selling and providing procedural solutions for spine surgery, with a guiding purpose to transform surgery, advance care and change lives. The company offers a portfolio of procedurally integrated spine surgery solutions, including surgical access instruments, spinal implants, fixation systems, biologics, and enabling technologies, as well as systems and services for intraoperative neuromonitoring. In addition, it develops and sells magnetically adjustable implant systems for the spine and specialized orthopedic procedures. The company also designs and sell expandable growing rod implant systems for the treatment of early-onset scoliosis that can be non-invasively lengthened after implantation with incremental adjustments via an external remote controller using magnetic technology called MAGneticExternal Control (MAGEC). The company operates in more than 50 countries serving surgeons, hospitals, and patients.

Industry: Surgical & Medical Instruments & Apparatus Peers: ABBOTT LABORATORIES AtriCure, Inc. Axonics, Inc. Enovis CORP CONMED Corp GLAUKOS Corp Integer Holdings Corp NEVRO CORP PROCEPT BioRobotics Corp TANDEM DIABETES CARE INC